Kimberly Stegmaier, MD
Associate Professor of Pediatrics, Harvard Medical School
Center/ProgramPediatric Hematologic Malignancies
Office phone: 617-632-4985
Preferred contact method: email
View Physician Profile
Chemical screening, Neuroblastoma, Ewing Sarcoma, Hematologic malignancies, Cancer genomics
Area of Research
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Kimberly Stegmaier, M.D., is an Associate Professor of Pediatrics at Harvard Medical School, a Principal Investigator in Pediatric Oncology at the Dana-Farber Cancer Institute (DFCI), and anAttending Physician at the Boston Children’s Hospital Boston (BCH) and DFCI. She is the Co-director of the Pediatric Hematologic Malignancies Program at DFCI and BCH and is also an Associate Member of the Broad Institute of Harvard and MIT. She received her B.S. from Duke University and her M.D. from Harvard Medical School. She completed her residency at BCH and a post-doctoral pediatric hematology-oncology fellowship at DFCI/BCH. In 2006, she launched her own laboratory effort at DFCI.
Dr. Stegmaier’s laboratory integrates chemical biology, genomic, and proteomic approaches to discover new lead compounds and protein targets for cancer therapy. She has focused her efforts on the acute leukemias and two pediatric solid tumors of childhood: Ewing sarcoma and neuroblastoma.
- Clifford Barger Excellence in Mentoring Award, Harvard Medical School, 2014
- Osler Young Investigator Award, Interurban Clinical Club, 2013
- Society for Pediatric Research (SPR) Young Investigator Award, 2012
- Stephen E. Sallan Leadership Award, 2012
- American Society for Clinical Investigation, Elected Member, 2009
- SU2C Innovative Research Grant Recipient, 2009
- Genome Technology “Tomorrow’s Principal Investigator” Award, 2007
- Joanne Levy, MD, Memorial Award for Outstanding Achievement, American Society of Hematology, 2006
My research program focuses on the integration of “omic” approaches for the identification of new protein targets and small-molecule modulators of malignancy with an eye toward clinical translation. Cancer discovery efforts in my laboratory have focused on the alteration of the malignant state (e.g., AML and neuroblastoma differentiation) and the modulation of pharmacologically challenging oncoproteins (e.g., EWS/FLI in Ewing sarcoma, MYCN in neuroblastoma, and NOTCH1 in T-ALL.) Most recently, we are applying an integrated approach to discover new therapeutic opportunities in these malignancies with deep genomic characterization of primary tumors, kinase activity profiling for immediately druggable targets, functional genomic screening for new tumor dependencies and chemical screening for modulators of relevant oncogenic drivers. Clinical trials for patients with AML and Ewing sarcoma have resulted from our research and a trial testing BET bromodomain inhibitors in patients with MYCN amplified neuroblastoma is in development.
- Crompton, Brian, MD
- Roti, Giovanni, MD, Ph.D.
- Banerji, Versha, MD, FRCP(c)
- Pikman, Yana, M.D.
- Puissant, Alexandre, Ph.D.
- Chen, Liying, Ph.D.
- Thorner, Aaron, Ph.D.
- Carnevale, Julia, HHMI Fellow, HMS Medical Student
- Li, Puyao C., HST/MIT-Harvard Student
- Vallurupalli, Mounica, HHMI Fellow, HMS Medical Student
- Patel, Sarvagna, HST Harvard/MIT Student